Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.47 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4635555 | 0.79 | DPP4 (0.49) | GRIN2BPLD1GRM1CYP3A4CYP2D6 | |
| SCHEMBL32690594 | 0.78 | GRM1 (0.57) | GRIN2BPLD1GRM1CYP3A4CYP2D6 | |
| SCHEMBL30556650 | 0.78 | GRIN2B (0.59) | GRIN2BPLD1GRM1CYP3A4CYP2D6 | |
| SCHEMBL29991351 | 0.75 | GRIN2B (0.49) | GRIN2BPLD1GRM1CYP3A4CYP2D6 | |
| SCHEMBL23875353 | 0.74 | PLD1 (0.52) | GRIN2BPLD1GRM1KDM4EALDH1A1 | |
| SCHEMBL2294733 | 0.74 | GRIN2B (0.55) | GRIN2BPLD1GRM1CYP3A4CYP2D6 | |
| SCHEMBL30937159 | 0.74 | GRIN2B (0.55) | GRIN2BPLD1GRM1CYP3A4CYP2D6 | |
| SCHEMBL16059501 | 0.74 | DPP4 (0.58) | GRIN2BPLD1GRM1CYP3A4CYP2D6 | |
| SCHEMBL2002068 | 0.74 | PLD1 (0.52) | GRIN2BPLD1GRM1CYP3A4CYP2D6 | |
| SCHEMBL16059500 | 0.74 | DPP4 (0.58) | GRIN2BPLD1GRM1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR5A1 | GRIN2B 1180/4885PLD1 4424/4885GRM1 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.